Related Experiment Videos
Adjuvant activity of incomplete Freund's adjuvant
1The Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008, USA
Advanced Drug Delivery Reviews
|June 6, 2000
Summary
Incomplete Freund's Adjuvant (IFA) enhances antibody responses and is well-tolerated in humans. Combining IFA with other compounds can improve cellular immunity, making it a versatile vaccine adjuvant.
Area of Science:
- Immunology
- Vaccinology
Background:
- Water-in-oil emulsion adjuvants, including Incomplete Freund's Adjuvant (IFA), are widely used in research and veterinary vaccines.
- IFA has demonstrated superior antibody response augmentation compared to adjuvants like alum in human trials and exhibits good tolerability.
Purpose of the Study:
- To evaluate the efficacy and safety of Incomplete Freund's Adjuvant (IFA) as a vaccine adjuvant.
- To explore methods for overcoming the limitations of IFA in stimulating cellular immune responses.
Main Methods:
- Review of existing research on IFA's performance in human and animal studies.
- Investigation of combination strategies using IFA with other adjuvant-active compounds like saponins and cytokines.
Main Results:
- IFA effectively augments antibody responses and is generally well-tolerated, with toxicity managed through high-grade components.
- While IFA alone may not optimally stimulate cellular immunity, its combination with other adjuvants shows promise in preclinical models.
Conclusions:
- IFA remains a valuable vaccine adjuvant due to its proven ability to enhance antibody production and its manageable safety profile.
- Formulations combining IFA with other immune-modulating agents offer a strategy to broaden its applicability, potentially addressing cellular immune response limitations.